Method of detecting drug taggants in biological samples to assess drug decay

Patent metadata

Field	Value
Publication number	US-10209264-B2
Application number	US-201715496407-A
Country	US
Kind code	B2
Filing date	Apr 25, 2017
Priority date	Apr 25, 2017
Publication date	Feb 19, 2019
Grant date	Feb 19, 2019

Abstract

We disclose a method of using taggants to assess how and to what extent a drug in a drug composition that a user has consumed has decayed in response to storage conditions and time. The taggants may decay in response to environmental conditions which cause different drugs to lose their efficacy. These environmental conditions may include light, temperature, oxidation, moisture, and age. The taggants may be detected in biological samples, including urine and feces. By identifying the taggants, the drug composition and other information relating to the drug may be identified. Additionally, quantification of the different taggants may be used to determine whether the drug in the drug composition has been exposed to environmental conditions which may reduce its efficacy.

First claim

We claim:

1. A method of detecting drug taggants in biological sample to assess decay of a drug in a drug composition comprising the steps of:
a) detecting a signal produced by a first and a second drug taggant in the biological sample which was collected from a user who has consumed at least one drug composition,
i. wherein each of the at least one drug composition comprises the following, each in a known quantity and in a first ratio, at the time of manufacture of the drug composition: at least one drug or placebo, and the first and the second drug taggants,
ii. wherein the first drug taggant comprises a first decay characteristic and the second drug taggant comprises a second decay characteristic,
iii. wherein the first decay characteristic is detectably different from the second decay characteristic, and
iv. wherein the at least one drug or placebo comprises the first and the second decay characteristics;
v. wherein the first decay characteristic and the second decay characteristic are independently selected from the following: decay due to light sensitivity, decay due to temperature sensitivity, and decay due to moisture;
vi. wherein the first decay characteristic is a qualitatively different characteristic than the second decay characteristic; and
vii. wherein the first decay characteristic is qualitatively the same as a decay characteristic possessed by the drug, and wherein the first decay characteristic is kinetically approximately the same as the decay characteristic possessed by the drug; and
viii. wherein the first drug taggant and the second drug taggant are independently selected from the following: polyethylene glycol, copovidone, povidone, propyl paraben, methyl paraben, acesulfame potassium, mannitol, sorbitol, xylitol, steviol glucuronide, sucralose, oleic acid, trans-anethole, 1,8-eucalyptol, limonene-2D, riboflavin, tartaric acid, salts of tartaric acid, linalool, and citronellol; and

b) calculating a second ratio of the first and the second drug taggants present in the biological sample;
c) identifying one or more decay characteristics which caused the decay of the drug; and
d) extrapolating a difference between the first ratio and the second ratio to determine a fraction of decayed drug.

2. The method of claim 1 , wherein the at least one drug composition comprises a placebo.

3. The method of claim 2 , wherein the first ratio is indicative of one of the following: drug composition manufacturer, at least one drug, drug composition, manufacturing batch, dispensing pharmacy, prescribing healthcare provider, healthcare provider's institution, and prescribed user.

4. The method of claim 1 , wherein either the first taggant or the second taggant consists of polyethylene glycol, and wherein the polyethylene glycol comprises polymers of one or more of the following average molecular weights: 400, 600, 800, 1000, 1500, and 2000.

5. The method of claim 1 , wherein either the first drug taggant, the second drug taggant, or both the first and second drug taggants consist of polyethylene glycol, and wherein the polyethylene glycol comprises polymers with an average molecular weight of between about 400 and about 2000.

6. The method of claim 1 , wherein either the first drug taggant, the second drug taggant, or both the first and second drug taggants consists of povidone molecules, and wherein the povidone molecules consist of one or more of the following number of monomers: 25, 30, and 90.

7. The method of claim 1 , wherein the biological sample comprises one or more of the following: urine, feces, whole blood, serum, plasma, cerebrospinal fluid, ascites, mucous, gastric gavage, breath, saliva, breath, and breast milk.

8. The method of claim 1 , wherein the first taggant and the second taggant are detectable in the biological sample using one or more of the following analytical techniques: gas chromatography-mass spectrometry, liquid chromatography, capillary zone electrophoresis with UV absorbance, high performance liquid chromatography with UV absorbance, reverse-phase chromatography, fluorescence spectroscopy, high performance thin layer chromatography, UV spectroscopy, infrared spectroscopy, near IR spectroscopy, mid-IR spectroscopy, visible spectroscopy, nuclear magnetic resonance, ion mobility spectrometry, liquid chromatography-ion mobility spectroscopy, liquid chromatography-electrochemical detection, liquid chromatography-UV spectroscopy with a normal UV photodetector, thin layer chromatography, liquid chromatography, Raman spectroscopy, colorimetric assay, and mass spectrometry.

9. The method of claim 8 , wherein the analytical technique is performed by an instrument connected to a medical toilet.

10. The method of claim 1 , wherein a concentration of the first drug taggant, a concentration of the second drug taggant, or the concentration of both the first and the second drug taggants in the drug composition at the time of manufacture of the drug composition is approximately the same as a concentration of the drug.

11. The method of claim 1 , wherein the first decay characteristic, the second decay characteristic, or both the first and the second decay characteristics are qualitatively the same as a decay characteristic of the drug.

12. The method of claim 1 , which further includes a third drug taggant, wherein the third drug taggant is stable in response to light, temperatures outside a range recommended for storage of the drug, oxygen exposure, moisture, and time relative to the first and second drug taggants.

13. The method of claim 12 , wherein the third drug taggant is cleared by the same biological system as the drug.

14. The method of claim 1 , wherein the concentration of the drug taggants, either individually or jointly, exceed the concentration of the drug, or drugs, by approximately between 50 percent and 100 percent.

Assignees

• Hall David R
• Allen Dan
• Rosenbrock Conrad
• Hendricks Daniel
• Nguyen Andrew
• Butala Steven J M
• Niederhauser Travis
• Pearman Terrece
• Fox Joe

Inventors

• Hall David R
• Allen Dan
• Rosenbrock Conrad
• Hendricks Daniel
• Nguyen Andrew
• Butala Steven J M
• Niederhauser Travis
• Pearman Terrece
• Fox Joe

Classifications

• A61B2010/0061

  Alimentary tract secretions, e.g. biliary, gastric, intestinal, pancreatic secretions · CPC title

• A47K17/00

  Other sanitary equipment not covered by the other groups of this subclass {; Holders for toilet brushes} · CPC title

• A61B5/15

  Devices for taking samples of blood · CPC title

• G01N33/58

  involving labelled substances (G01N33/53 takes precedence) · CPC title

• G01N33/493

  urine · CPC title